

Rajesh Chopra: Bibliography

Publications

A total of 97 peer reviewed publications in academic journals together with 29 additional publications comprising reviews, book chapters and symposium proceedings.

Papers published in peer review journals

1. **Chopra R**, Goldstone AH, McMillan A et al. Successful treatment of AML beyond first remission with autologous bone marrow transplantation using busulphan/cyclophosphamide and unpurged Marrow - The British Autograft Group (B.A.G.) experience. *Journal of Clinical Oncology* 1991; 9 (10):1840-1847
2. Lim S, McMillan A, **Chopra R**, Salooja N, Cervi P, Goldstone AH Peri-transplant septicaemia in patients undergoing ABMT for acute leukaemia and lymphoma. *Leukaemia and Lymphoma* 1991;3,23-2
3. Wilson APR, Felmingham D, Robbins M, **Chopra R**. Enterococcus-Faecium sensitive to teichoplanin but not vancomycin. *Journal of Hospital Infection* 1991;18(4):322-324
4. Khwaja A, **Chopra R**, Goldstone AH, Linch DC (1991) Acute phase response in patients given rhIL-3 after chemotherapy. *Lancet* 1991; 339:1617
5. Khwaja A, Yong K, Jones HM, **Chopra R**, McMillan AK, Goldstone AH, Patterson KG, Matheson C, Ruthven K, Abramson SB, Linch DC. The effect of macrophage colony - stimulating factor on haemopoietic recovery after autologous bone marrow transplantation. *British Journal of Haematology* 1992;81(2):288-295
6. Collins PW, Gutteridge CN, O'Driscoll A, Blair S, Jones L, Aitchison R, Kelsey SM, **Chopra R**, Goldstone AH, Newland AC. von Willebrand factor as a marker of endothelial cell activation following BMT. *Bone Marrow Transplantation* 1002;10 (6):499-506
7. **Chopra R**, Goldstone AH, Pearce R, Philip T, Petersen F, Appelbaum F, DeVol E, Ernst P. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case controlled analysis of the European Bone Marrow Transplant Registry data. *Journal of Clinical Oncology* 1992;10 (11):1160-1695
8. Khwaja A, Linch DC, Goldstone AH, **Chopra R**, Marcus R et al. Recombinant human granulocyte colony stimulating factor after autologous bone marrow transplantation for malignant lymphoma. A British National Lymphoma Investigation double blind placebo trial. *British Journal of Haematology* 1992;82(2):317-323
9. **Chopra R**, Linch DC, McMillan AK, Blair S, Patterson KG, Moir D, Richards JDM, Cervi P, Kinsey S, Goldstone AH. (1992) Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's Disease. *British Journal of Haematology* 1992;81(2):288-295
10. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, **Chopra R**, Milligan D, Vaughan Hudson G. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. *Lancet* 1993;341:1051-1054
11. **Chopra R**, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center, eight year study of 155 patients. *Blood* 1993; 81: 1137-1145

12. **Chopra R**, Linch DC, Goldstone AH. The University College and Middlesex Hospital's approach to primary treatment of diffuse large cell lymphomas. *Hematology /Oncology Annals* 1993; 1:41-46
13. Brink NS, **Chopra R**, Perrons CJ, Ring CJA, Garson JA, Goldstone AH, Linch DC, Tedder RS. Acute hepatitis C infection in patients undergoing therapy for haematological malignancies: a clinical and virological study. *British Journal of Haematology* 1993;83:498-503
14. Brink NS, Mills W, **Chopra R**, Garson JA, Perrons CJ, Deaville RC, Waite J, Goldstone AH, Linch DC, Tedder RS. Efficacy of donor screening for hepatitis C antibodies in preventing hepatitis C infection in multiply transfused patients. *Transfusion Medicine* 1993;3:291-294
15. Linch DC, Scarffe H, Proctor S, **Chopra R**, Taylor PRA et al. Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. *Bone Marrow Transplantation* 1993;11:307-311
16. Grimwade DJ, **Chopra R**, King A, Shaw P, Linch DC, Goldstone AH. The detection and significance of pulmonary Hodgkin's disease at ABMT. *Bone Marrow Transplantation* 1994;13:173-179
17. Mills W, **Chopra R**, Linch DC, Goldstone AH. Liposomal amphotericin in the treatment of fungal infections in neutropenic patients. *British Journal of Haematology* 1994;86:754-760
18. **Chopra R**, Wotherspoon AC, Blair S, McMillan AK, Mills W, Fielding, Linch DC, Goldstone AH. Detection and significance of bone marrow involvement in Hodgkin's disease. *British Journal of Haematology* 1994;87:647-649
19. Collins P, Roderick A, O'Brien D, O'Driscoll A, **Chopra R**, Goldstone AH, Newland A. Factor VIIa and other haemostatic variables following bone marrow transplantation. *Thrombosis and Haemostasis* 1994;72:28-32
20. Mills W, **Chopra R**, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed and refractory non-Hodgkin's lymphoma. *Journal of Clinical Oncology* 1995;13:588-595
21. **Chopra R**, Kendall G, Gale RE, Thomas NSB, Linch DC. Expression of two alternatively spliced forms of the 5' untranslated region of the granulocyte macrophage colony stimulating factor mRNA. *Experimental Haematology* 1996;24:755-762
22. Gale RE, Freeburn R, Khwaja A, **Chopra R**, Linch DC. A truncated isoform of the human α chain common to the receptors for granulocyte-macrophage colony stimulating factor, interleukin-3 and interleukin-5 with increased mRNA expression in some patients with acute myeloid leukaemia. *Blood* 1998;91:54-63
23. Cambier N, **Chopra R**, Strasser A, Metcalf D and Elefanty AG. (1998) Bcr-abl activates distinct pathways mediating cytokine independence and protection against apoptosis in murine haemopoietic cells in a dose dependent manner. *Oncogene* 1998;16:335-48
24. Clarke A, McKendrick S, Campbell M, Tansey P, Franklin I, **Chopra R**. A comparative analysis of lipid complexed and liposomal amphotericin B preparations in Haematological Oncology. *British Journal of Haematology* 1998;103:198-204
25. McColl MD, Corser RB, Bremner J, **Chopra R**. Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin. *Bone Marrow Transplantation* 1998;21:423-5
26. **Chopra R**, Guiver M, Barnes AJ, Oppenheim BA, Mutton K, Chang J, Morgenstern GR, Scarffe JH. Quantitative real time PCR for the management of CMV infection in patients undergoing bone marrow transplantation. *Haematologica* 1999;84:69

27. Eaton D, **Chopra R**, Chang J, Taberner D, Morgernstern GR, Leeming D, Iacobelli M, Scarffe JH. Defibrotide is an effective agent for the treatment of hepatic veno-occlusive disease, and response may be monitored using PAI-1 levels. *Haematologica* 1999; 84:68
28. Robertson J, Gale RE, Wynn R, Linch DC, Testa NG, **Chopra R**. Dynamics of Telomere shortening in Neutrophils and T-lymphocytes during ageing and relationship to acquired skewing of X-chromosome inactivation patterns. *British Journal of Haematology* 2000; 108:1-9.
29. Ased S, **Chopra R**, Robertson J and Testa NG Detection of hTERT Protein by flow cytometry *Leukaemia* 2000;12:2176-2181
30. Champlin R, Horowitz M, Schmitz N, Chapuis B, **Chopra R**, et al. On behalf of IBMTR and EBMT. Blood stem cells versus bone marrow as a source of haemopoietic cells for allogeneic transplantation. *Blood* 2000;95:3702-3709
31. Kottarides P, Milligan D, **Chopra R** et al Campath 1H prevents GVHD without compromising a GVL effect after low intensity regimen transplantation *Blood* 2000;96:2419-2425
32. Robertson J, Russell N, Stainer C, Jackson G, Parker A, Milligan D, Chakraverty S, Testa N and **Chopra R**. Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant. *Bone Marrow Transplantation* 2001; 27:1283-1286
33. **Chopra R**, Eaton JD, Barbui T et al. Defibrotide is an effective therapy for severe hepatic veno-occlusive disease: results of the European Compassionate use study. *British Journal of Haematology* 2001;111:1122-1122
34. Quamruddin A, Oppenheim B, Guiver M, Mutton K, and **Chopra R**. Screening for CMV in allogeneic bone marrow transplantation using a quantitative whole blood PCR method: analysis of potential risk factors for CMV infection. *Bone Marrow Transplantation* 2001;27:301-306
35. Chakraverty R, Peggs K, **Chopra R**, Milligan D, Kottarides P, Verfeuth S, Geary J, Thuraisundaram D, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams C, Yong k, Linch DC, Goldstone AH, Mckinnon S (2001). Limiting transplant related mortality following unrelated donor stem cell transplantation using a non-myeloablative conditioning regimen. *Blood* 99, 1071-78
36. Chakrabarti S, Mckinnon S, **Chopra R**, Kottarides PD, Peggs K, O'Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P, Craddock C, Waldmann H, Hale G, Fegan C, Yong K, Goldstone AH, Linch DC, Milligan D. High Incidence of cytomegalovirus infection after Nonmyeloablative Stem Cell transplantation: potential Role of CAMPATH-1H in delaying immune reconstitution but limiting transplant related mortality. *Blood* 2001;99:4357-63
37. Macheta M, **Chopra R**, Morgenstern G, Chang J. Chemotherapy for leukaemia following previous radiotherapy is associated with severe enteritis and haemorrhagic cystitis. *Annals of Hematology* 2001; 80:485-487.
38. Branson K, **Chopra R**, Kottaridis P, Parker A, Milligan D, Chakrabarti S, Craddock C, Schey S, Marsh J, Williams C, Goldstone AH, Linch DC, Mckinnon S. The role of nonmyeloablative allogeneic stem cell transplantation after failure of autologous transplant in patients with lymphoid malignancy *Journal of Clinical Oncology* 2002; 20(19):4022-31.
39. Callow CR, Swindell R, Randall W and **Chopra R**. The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. A single centre study. *British Journal of Haematology* 2002; 118(2):677-82.
40. JA Perez-Simon, P Kottaridis, R Martino, C Craddock, D Caballero, **R Chopra**, C Solano, D Milligan, S Sky, A Urbano-Ispizua, A Parker, A Sureda, A Hunter, J Sierra, A Hunter, DC Linch, JF San Miguel, S Mackinnon. Non-Myeloablative Transplants with or without Campath-1H: Comparison

- between two prospective trials in patients with Lymphoproliferative Disorders. *Blood* 2002; 100:3121-7.
41. Marks D, Lush R, Cavenagh J, Milligan D, Schey S, Parker A, Clark F, Hunt L, Yin J, Fuller S, Vandenberghe E, Marsh J, Littlewood T, Smith GM, Culligan D, Hunter A, **Chopra R**, Davies A, Towlson K, Williams CD. The Toxicity and efficacy of donor lymphocyte infusion given after reduced intensity conditioning allogeneic stem cell transplantation. *Blood* 2002; 100:3108-14.
 42. Tatton L, Morley GM, **Chopra R**, Khwaja A. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. *Journal of Biol Chem*. 2003; 278(7):4847-53.
 43. Kaleel R, Eaton D, Chang J, Leeming D, **Chopra R**. Role of PA1-I levels in monitoring response to Defibrotide in hepatic veno-occlusive disease. *Haematology* 2003; 8(2):91-5.
 44. Kottaridis PD, Milligan DW, **Chopra R**, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuert S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, Ruiz de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, MacKinnon S. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. *Cytotherapy* 2003; 3(3):197-201.
 45. Hassan IA, **Chopra R**, Swindell R, Mutton K. Respiratory viral infections after bone marrow/peripheral stem cell transplantation: the Christie Hospital Experience. (*Bone Marrow Transplantation* 2003; 32(1):73-7.
 46. Ewing JC, Robertson JD, Kell JW, Burnett AK, Ryder D, Chang J, Morgenstern GR, Scarffe JH and **Chopra R**. Peripheral Blood Stem Cell Transplantation in First Remission Adult Acute Myeloid Leukaemia – An Intention to Treat Analysis and Comparison of Outcome with a Predictive Model Based on the MRC AML10 Cohort. *Haematology* 2003; 8(2):83-90.
 47. Slater N, Yamaguchi M, Rothwell D, Baker P, Heyworth C, **Chopra R**. The human GM-CSFR alpha2 isoform influences hemopoietic lineage commitment and divergence via a JAK2 independent pathway. *British Journal of Haematology* 2003; 122(1):150-8.
 48. Kell J, Burnett AK, **Chopra R**, Yin J, Clark RE, Rohatiner A, Culligan D, Hunter A, Prentice AG, Milligan D. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. *Blood* 2003; 102(13):4277-83.
 49. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith GM, Parker A, Schey S, **Chopra R**, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S. Outcome Following Alemtuzumab (CAMPATH-1H) -Containing Reduced Intensity Allogeneic Transplant Regimen for Relapsed and Refractory Non-Hodgkin's Lymphoma (NHL). *Blood* 2004; 104(13):3865-71.
 50. Naylor CS, Jaworska E, Branson K, Embleton MJ, **Chopra R**. Side population/ABCG2-positive cells represent a heterogeneous group of haemopoietic cells: implications for the use of adult stem cells in transplantation protocols. *Bone Marrow Transplantation* 2005; 35(4):353-60.
 51. Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, Wedel N, Roboz GJ, Miller C, **Chopra R**, Jurcic JC, Brown R, Ehmman WC, Schulman P, Frankel SR, De Angelo D, Scheinberg D. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. *J Clin Oncol* 2005;23(18):4110-6
 52. Rowe JM, Buck G, Burnett AK, **Chopra R**, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, Prentice HG, Durrant J, Tallman MS, Goldstone AH; ECOG; MRC/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of

more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. *Blood* 2005; 106(12):3760-7.

53. Delgado J, Thomson K, Russell N, Ewing J, Stewart W, Cook G, Devereux S, Lovell R, **Chopra R**, Marks DI, Mackinnon S, Milligan DW; British Society of Blood and Marrow Transplantation Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. *Blood*. 2006; 107(4):1724-30.
54. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, Marsh J, Milligan D, Goldstone A, Hunter A, Khwaja A, **Chopra R**, Littlewood T, Peniket A, Parker A, Jackson G, Hale G, Cook M, Russell N, Mackinnon S. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. *J Clin Oncol*. 2005; 23(36):9387-93.
55. Lazarus HM, Richards SM, **Chopra R**, Litzow MR, Burnett AK, Wiernik PH, Franklin IM, Tallman MS, Cook L, Buck G, Durrant IJ, Rowe JM, Goldstone AH. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis. Results from the International ALL Trial MRC UKALL-XII/ECOG E2993 *Blood* 2006 108(2):465-72
56. Sirohi B, Powles RL, **Chopra R**, Russell N, Byrne JL, Prentice HG, Potter M, Koblinger S. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2006 38(1):47-51
57. Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, **Chopra R**, Clark R, Levis MJ, Small D. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. *Blood* 2006; 108(10):3262-70.
58. Fielding AK, Richards SM, **Chopra R**, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, McMillan AK, Tallman MS, Rowe JM, Goldstone AH; Medical Research Council of the United Kingdom Adult ALL Working Party; Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. *Blood*. 2007; 109(3):944-50.
59. Yamaguchi M, Fujimura K, Toga H, Khwaja A, Okamura N, **Chopra R**. Shwachman-Diamond syndrome is not necessary for the terminal maturation of neutrophils but is important for maintaining viability of granulocyte precursors. *Exp Hematol* 2007;35(4):579-86
60. Ruell J, Barnes C, Mutton K, Foulkes B, Chang J, Cavet J, Guiver M, Menasce L, Dougal M, **Chopra R**. Active CMV disease does not always correlate with viral load detection. *Bone Marrow Transplant*. 2007;40(1):55-61
61. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, **Chopra R**, Wiernik PH, Foroni L, Paietta E, Litzow MR, Marks DI, Durrant J, McMillan A, Franklin IM, Luger S, Ciobanu N, Rowe JM. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). *Blood* 2008;111(4):1827-33
62. Jackson D, Herath A, Swinton J, Bramwell D, **Chopra R**, Hughes A, Cheeseman K, Tonge R. (2009) Considerations for powering a clinical proteomics study: Normal variability in the human plasma proteome. *Proteomics* 2009;3:394-407
63. Lopez-Girona A, Heintel D, Zhang LH, Mendy D, Gaidarova S, Brady H, Bartlett JB, Schafer PH, Schreder M, Bolomsky A, Hilgarth B, Zojer N, Gisslinger H, Ludwig H, Daniel T, Jäger U, and **Chopra R** (2010) Lenalidomide down regulates the cell survival factor IRF4 and is predictive of response. *Br J Haematol* 2011;154(3):325-36

64. **Yamaguchi M**, Fujimura K, Kanegane H, Toga-Yamaguchi H, **Chopra R**, Okamura N. Mislocalization or low expression of mutated Shwachman-Bodian-Diamond syndrome protein: Int J Hematol. 2011;94(1):54-62.
65. Mamidipudi V, Shi T, Brady H, Surapaneni S, **Chopra R**, Aukerman SL, Heise C, Sung V. Amrubicin is Active in Anthracycline-Resistant Cells Via a Distinct Mode of Action and Cellular Accumulation and Distribution: Cancer Chemother Pharmacol. 2012; 965-76
66. Antonia Lopez-Girona, , Derek Mendy, Karen Miller, Anita K Gandhi, Jian Kang, Gilles Carmel, Mahan Abbasian, Afshin Mahmoudi, Pilgrim Jackson, Brian Cathers, Emily Rychak, Normand Richard, Helen A Brady, Peter H Schafer, Jilly F Evans, Tom O Daniel¹ and **Rajesh Chopra^a** Direct Binding with Cereblon Mediates the Antiproliferative and Immunomodulatory Action of Lenalidomide and Pomalidomide; Leukemia. 2012; 2326-35
67. Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, **Chopra R**. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2013;160(4):487-502
68. Soraya Carrancio, Jennifer Markovics, Piu Wong, Jim Leisten, Paola Castiglioni, Matthew C. Groza, Heather K. Raymon, Carla Heise, Tom Daniel, **Rajesh Chopra**, Victoria Sung¹ Sotatercept, an Activin Receptor IIa Ligand Trap, Promotes Late-Stage Erythropoiesis Resulting in a Rapid Induction of Red Blood Cell Number and Hemoglobin Br J Haematol. 2014 Jun; 165(6):870-82.
69. Anita K Gandhi, Derek Mendy, Michelle Waldman, Sharon L Aukerman, Gengxin Chen, Emily Rychak, Karen Miller, Svetlana Gaidarova, Yan Ren, Maria Wang, Michael Breider, Michael Gonzales, Gilles Carmel, Afshin Mahmoudi, Pilgrim Jackson, Mahan Abbasian, Brian E Cathers, Peter H Schafer, Tom O Daniel, Antonia Lopez-Girona, , Anjan Thakurta and **Rajesh Chopra** Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity Br J Haematol. 2013 Feb;160(4):487-502
70. Anita Gandhi; Tao Shi; Mingyu Li; Ulf Jungnelius; Alfredo Romano; Josep Taberbero; Salvatore Siena; Peter Schafer; **Rajesh Chopra** Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined With Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients PLOS One 2013 Nov 11;8
71. Anjan Thakurta, Anita K Gandhi, -Suzanne Lentzsch, Steve A. Schey, Yolanda Calle, Rajani Chelliah, Robert Z. Orlowski, Chad Bjorklund, Anup Madan, Michelle Waldman , Herve Avet-Loiseau **Rajesh Chopra** Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD® therapy Leukemia 2013 Oct 29
72. Michael Dussiot, Thiago Trovati Maciel, Aurélie Fricot, Joel Veiga, Etienne Paubelle, Emmanuel Payen, Yves Beuzard, Jean Antoine Ribeil, Jean-Benoit Arlet, Francine Coté, Geneviève Courtois, Thomas O. Daniel, **Rajesh Chopra**, Victoria Sung, Olivier Hermine and Ivan Cruz Moura Targeting ActRIIa signaling improves anemia and corrects ineffective erythropoiesis in β -thalassemia Nature Medicine *in press*
73. Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, Ito T, Ando H, Waldman MF, Thakurta A, Klippel A, Handa H, Daniel TO, Schafer PH, **Chopra R**. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4^{CRBN}. Br J Haematol. 2013.

74. Chen X, Díaz-Rodríguez E, Ocio EM, Paiva B, Mortensen DS, Lopez-Girona A, **Chopra R**, Miguel JS, Pandiella A Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy. *Mol Cancer Ther.* 2014.
75. Rajasekhar Suragani , Samuel Cadena , Sharon Cawley , Dianne Sako , Dianne Mitchell , Mr. Robert Li , Monique Davies , Mark Alexander , Matthew Devine Kenneth Loveday ,. Kathryn Underwood, Asya Grinberg, John Quisel, **Rajesh Chopra**, Scott Pearsall. Jas S. Seehra TGF- β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. *Nature Medicine Nat Med.* 2014:408-14.
76. Wei Wei , Young Shik Shin , Tomoo Matsutani , Dr. Kenta Masui , Huiyun Yang , Yuchao Gu , Herrmann Ken , Kiwook Hwang , Prof. Bruno Bonetti , **Dr. Rajesh Chopra** , Dr. David James , Dr. Webster Cavenee , Dr. Timothy Cloughesy , Dr. Paul Mischel , Beatrice Gini Single Cell Phosphoproteomics identifies adaptive network dynamics of mTOR inhibitor resistance and defines effective combination therapy in glioblastoma *Nature Medicine* (in review)
77. Johanna C. Bendell, Robin K. Kelley, Kent C. Shih, Anne Reinert, Emily Bergsland, Suzanne Jones, Thomas Martin, Jeffrey R. Infante, Paul S. Mischel, Tomoo Matsutani, Shuichan Xu, Lilly Wong, Yong Liu, Xiaoling Wu, Deborah S. Mortensen, **Rajesh Chopra**, Kristen Hege, Pamela N. Munster A. Phase 1 Dose Escalation Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the Dual mTORC1/mTORC2 Kinase Inhibitor CC-223, in Patients With Advanced Solid Tumors or Multiple Myeloma (*Cancer in press*)
78. Nianhang Chen, Yan Li, Ying Ye, Maria Palmisano, **Rajesh Chopra**, Simon Zhou. Pharmacokinetics and Pharmacodynamics of nab Paclitaxel in Patients With Solid Tumors: Disposition Kinetics and Pharmacology Distinct From Solvent-Based Paclitaxel *Journal of Clinical Pathology J Clin Pharmacol.* 2014:10.1002/jcph.304
79. Chen N, Li Y, Ye Y, Palmisano M, **Chopra R**, Zhou S Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel. *J Clin Pharmacol.* 2014 10.1002/jcph.304.
80. Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, Man HW, Muller GW, Stirling DI, **Chopra R**. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. *Cell Signal.* 2014: S0898-6568(14)00190-9.
81. Nianhang Chen, Carrie Brachmann, Xiping Liu, Daniel W. Pierce, Joyoti Dey, William S. Kerwin, Yan Li, Simon Zhou, Shihe Hou, Michael Carleton, Richard A. Klinghoffer, Maria Palmisano, and **Rajesh Chopra** Albumin-bound nanoparticle (*nab*) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration (*Cancer Chemotherapy and Pharmacology in press*)
82. RA. Klinghoffer SB. Bahrami, BA. Hatton, J Frazier, A Moreno-Gonzalez, A Strand, W. Kerwin, J. Casalini, D. Thirstrup, S. You, M. Veiseh, M Grenley, I Tretyak, J. Dey, M. Carleton, E. Beirne, K. Pedro, S. Ditzler, E. Girard, T. Deckwerth, E. Filvaroff, **R. Chopra**, J. M. Olson. CIVO™: A technology platform to assess multiple drugs or drug combinations simultaneously within a single living tumor *Science Translational Medicine* 2015:7-284.
83. Jan Krönke, Emma C Fink, Kyle MacBeth, Slater N. Hurst, Namrata D. Udeshi, Philip P. Chamberlain, Anita Gandhi, D.R. Mani, Tanya Svinkina, Rebekka K. Schneider, Marie McConkey, Elizabeth Griffiths, Martin Carroll, Marcus Järås, Michelle Chen, Lars Bullinger, Brian E. Cathers, Steven A. Carr, **Rajesh Chopra**, Benjamin L. Ebert Lenalidomide induces ubiquitination and degradation of casein kinase 1a1 in del(5q) MDS (*Accepted as full article in Nature*)

84. Peter H. Schafer, Peng Chen, Lorraine Fang, Andrew Wang, **Rajesh Chopra**. The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase 3, Randomized, Controlled Trial (PALACE 1). *J Immunol Res.*;2015:906349.
85. Patrick R. Hagner, Hon-Wah Man, Maria Wang, Suzana Couto, Mike Breider, Celia Fontanillo, Chad Bjorklund, Courtney G. Havens, Gang Lu, Emily Rychak, Heather Raymon, Rama Krishna Narla, Leo Barnes, Hsiling Chiu, Jolanta Kosek, Jian Kang, Michael D. Amantangelo, Michelle Waldman, Antonia Lopez-Girona, Ti Cai, Michael Pourdehnad, Matthew Trotter, Thomas O. Daniel, Peter H. Schafer, Anke Klippel, Anjan Thakurta, **Rajesh Chopra**^{1*}, Anita K. Gandhi CC-122, a pleiotropic pathway modifier, mimics an interferon response and has broad antitumor activity in DLBCL. *Blood* 2015:2015-02-628669.
86. Michel Jourdan, Maïlys Cren, Peter Schafer, Nicolas Robert, Christophe Duperray, Laure Vincent, Patrice Ceballos, Guillaume Cartron, Jean- François Rossi, **Rajesh Chopra** and Bernard Klein Differential effects of lenalidomide during plasma cell differentiation. (Submitted to *Leukemia*)
87. Yan Ren, Maria Wang, Suzana Couto, Donna Hansel, Karen Miller, Antonia Lopez-Girona, Chad Bjorklund, Anita K. Gandhi, Anjan Thakurta, **Rajesh Chopra** and Michael Breider. A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples. (Laboratory Investigation in press)
88. Jos L.J. van der Velden¹, Ying Ye², James D. Nolin¹, Sidra M. Hoffman¹, David G. Chapman¹, Karolyn G. Lahue¹, Sarah Abdalla¹, Peng Chen³, Yong Liu², Brydon Bennett⁴, Nasreen Khalil⁵, Donna Sutherland³, William Smith³, Gerald Horan², Mahmoud Assaf, Zebulun Horowitz, **Rajesh Chopra**, Randall M. Stevens, Maria Palmisano, Yvonne M.W. Janssen-Heininger, Peter H. Schafer C-jun N-terminal kinase inhibition reduces lung remodeling and systemic markers of pulmonary fibrosis. (submitted to *Science Translational Medicine*)
89. Jason Ear, Haigen Huang, Tianna Wilson, Zahra Tehrani¹, Anne Lindgren¹, Victoria Sung, Abderrahmane Laadem, Thomas O. Daniel, **Rajesh Chopra**, and Shuo Lin RAP-011 Improves Erythropoiesis in Zebrafish Model of Diamond-Blackfan Anemia through Antagonizing Lefty1 (*Blood* in press)
90. Kathryn Lagrue, Alex Carisey, David Morgan, **Rajesh Chopra** and Daniel M. Davis Lenalidomide augments actin remodeling and lowers NK cell activation thresholds. *Blood*. 2015:01-625004.
91. Chen N, Brachmann C, Liu X, Pierce DW, Dey J, Kerwin WS, Li Y, Zhou S, Hou S, Carleton M, Klinghoffer RA, Palmisano M, **Chopra R**. Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. *Cancer Chemother Pharmacol*. 2015 Oct;76(4):699-712. doi: 10.1007/s00280-015-2833-5. Epub 2015 Aug 1.
92. Chad C. Bjorklund, Ling Lu, Jian Kang, Patrick R. Hagner, Courtney G. Havens, Michael Amantangelo, Maria Wang, Yan Ren, Mike Breider, Yuhong Ning, Anita K. Gandhi, Tom O. Daniel, **Rajesh Chopra**, Anke Klippel, and Anjan G. Thakurta Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of 2 lenalidomide and pomalidomide in Multiple Myeloma cells by regulation of c-Myc and IRF4 (submitted to *Leukemia*)
93. Rychak E, Mendy D, Shi T1, Ning Y, Leisten J, Lu L, Miller K, Narla RK, Orlowski RZ, Raymon HK, Bjorklund CC, Thakurta A, Gandhi AK, Cathers BE, **Chopra R**, Daniel TO, Lopez-Girona A. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in

pre-clinical models of lenalidomide-resistant multiple myeloma. *Br J Haematol.* 2016 Mar;172(6):889-901.

94. Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, Li X, Bonetti B, **Chopra R**, James CD, Cavenee WK, Cloughesy TF, Mischel PS, Heath JR, Gini B (2016). Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. *Cancer Cell.* 2016;29(4):563-73.
95. van der Velden JL, Ye Y, Nolin JD, Hoffman SM, Chapman DG, Lahue KG, Abdalla S, Chen P, Liu Y, Bennett B, Khalil N, Sutherland D, Smith W, Horan G, Assaf M, Horowitz Z, Chopra R, Stevens RM, Palmisano M, Janssen-Heininger YM, Schafer PH. JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers. *Clin Transl Med.* 2016;40169-016-0117-2.
96. Ear J, Hsueh J, Nguyen M, Zhang Q, Sung V, **Chopra R**, Sakamoto KM, Lin S. A Zebrafish Model of 5q-Syndrome Using CRISPR/Cas9 Targeting RPS14 Reveals a p53-Independent and p53-Dependent Mechanism of Erythroid Failure. *J Genet Genomics.* 2016;307-18.
97. Collins I, Wang H, Caldwell JJ, **Chopra R**. Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway. *Biochem J.* 2017;15;474.

Letters published in peer review journals

1. Khwaja A, Chopra R, Goldstone AH, Linch DC (1992) Acute phase response in patients giving rhIL-3 after chemotherapy. *Lancet* 339 (8809), 1617.
2. McMillan A, **Chopra R**, Pearce R, Goldstone AH, Linch DC. (1992) Treatment of Hodgkin's Lymphoma. *British Medical Journal*, 305 (6849), 367.
3. Brown JE, Olulohungbe A, Chang J, Ryder WD, Morgenstern GR, **Chopra R** and Scarffe JH. (2001) All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia. *British Journal of Hamatology*, 110, 1010-2.

Reviews articles

4. **Chopra R**, Blair S, Strang J, Cervi P, Patterson KG and Goldstone AH. (1991) Liposomal amphotericin in the treatment of fungal infections in neutropenic patients. *Journal of Antimicrobial Chemotherapy*, 28, 93-104.
5. **Chopra R**, Fielding A, Goldstone AH (1992). Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin B (AmBisome) - a report on 40 cases from a single centre. *Leukaemia and Lymphoma*, 7, 73-77.
6. **Chopra R** (1992) Management of acute myeloid leukaemia. *British Journal of Hospital Medicine*, 48, 363-375.
7. **Chopra R** and Goldstone AH (Guest Editors) (1992) Autologous Bone Marrow Transplantation Symposium (held at University College) September 1991. *Leukaemia and lymphoma*, 17 (suppl. 1) 662-676.
8. **Chopra R** and Goldstone AH. (1992) Modern trends in bone marrow transplantation for acute myeloid and acute lymphoblastic leukemia. *Current Opinion in Oncology*, 4, 247-258.
9. **Chopra R**, Goldstone AH. (1994) Advances in Hodgkin's Disease and future prospects. *Current Opinions in Haematology*, 1, 285-294.

10. **Chopra R** and Elefanty A. (1999) The Biology of BCR-ABL. *Blood Reviews* 13, 200-39.
11. **Chopra R.** AmBisome in the treatment of fungal infections: the UK experience (2002). *Journal of Antimicrobial Chemotherapy*, 49, 43-47.
12. Bishton M and **Chopra R.** (2004) The role of granulocyte transfusions in neutropenic patients. *Brit J Haematol* 127(5):501-8.
13. Campbell D, Carmichael J, **Chopra R** (2004) Molecular pathology in oncology: the industrial perspective. *Pharmacogenetics*;5(8):1167-73.
14. Heise C, Carter T, Schafer P, **Chopra R.** Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. *Expert Rev Anticancer Ther* 2010;10(10):1663-72.

Articles published as symposium proceedings

15. **Chopra R**, McMillan A, Goldstone AH, Linch DC. Double autologous bone marrow transplantation in 37 patients with leukaemia and lymphoma. *Proceedings of the Vth international Symposium on Autologous Blood and Marrow Transplantation* 1990: 101-106.
16. **Chopra R**, Goldstone AH. Progress for the future in lymphoma transplantation. *Proceedings of the Vth international Symposium on Autologous Blood and Marrow Transplantation* 1990: 50-58
17. **Chopra R**, Goldstone AH. The non-Hodkins lymphomas. Educational Book, International Society of Haematology 1993;Vienna, Springer Verlag
18. **Chopra R** The Third UCH High Dose Meeting. *Bone Marrow Transplantation* 1994;3:317-319
19. **Chopra R** High Dose Therapy: The Third UCH Meeting. *British Journal of Cancer* 1994;69:788-791
20. Robertson J and **Chopra R.** Long-term complications of stem cell transplantation in Hodgkins Disease. *Proceedings of the Xth International Symposium on Autologous Blood and Marrow Transplantation* 2000

Chapters in Books

21. **Chopra R**, Goldstone AH. (1992) The Role of Bone Marrow Transplantation in Lymphoma. In: *Bone Marrow Transplantation in Practice*. Eds: Treleaven and Barrett. Churchill Livingstone, pp 87-104.
22. Goldstone AH, McMillan AK, **Chopra R.** (1992) High Dose Therapy for the treatment of non-Hodgkin's Lymphoma. In: *High-Dose Cancer Therapy: Pharmacology, Haematopoietins, Stem Cells*. Eds: Armitage JO and Antman KH.
23. **Chopra R** and Goldstone AH (1997) The role of high dose therapy in lymphoblastic lymphomas In: *The Lymphomas*. Eds Armitage JO and Vose J.
24. **Chopra R** and Goldstone AH (1997) Lymphoblastic lymphoma In: *The Lymphomas*. Eds Armitage JO and Vose J.
25. J.A. Steele, S.D.J. McArthur, J.R. McDonald, A.H. Goldstone **R. Chopra**, "Knowledge Discovery in Databases:What Factors Influence a Successful Bone Marrow Transplant for Hodgkin's Disease", IEE Knowledge Discovery and Data Mining Colloquium, London, May, 1998.
26. **Chopra R** and Scarffe JH (2000) The Biology and Clinical Use of Stem cell factor. In: *High-Dose Cancer Therapy: Pharmacology, Haematopoietins, Stem Cells*. Eds: Armitage JO and Antman KH.
27. Chakravarty R, Goldstone AH, Mcmillan AK, **Chopra R** (2000) High dose Therapy for the treatment of NHL. In eds: Armitage JO and Antman KH, *High-Dose Cancer Therapy: Pharmacology, Haematopoietins, Stem Cells*, Wilkins.

Professor Rajesh Chopra BSc, MBBS, FRCP, FRCPath, PhD

28. Ewing J and **Chopra R**. (2001) The role of autologous transplantation in acute leukaemia. In: High dose chemotherapy. Eds: Lorigan P and Van den Burgh E. Martin Dunitz.
29. O'Gorman P and **Chopra R** (2001) Evidence for the empirical use of anti-fungal therapy: clinical reasoning underpinning the selection of anti-fungal agents. In: Key advances in the effective prevention and management of Series Systemic Fungal Infection in Haematological Malignancy, Eds, Cornish J, Miles A, Prentice A, Prentice HG and Rogers T. Aesula PWS Medical press.

Journal Editorships

Editorial Board of Haematology, Harwood Academic Publishers

British Journal of Haematology Blackwell

Editor, CME Bulletins, RILA Publications – this bulletin is circulated to every Haematologist and is recognised by the Royal College of Pathologists

Patents

Inventors: Hagner P, Gandhi A, Chopra R, A Klippel (2016). Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies. PCT Publication no. WO2016060702

Inventors: Gandhi A, MF Waldman, Chopra R, M Amatangelo, Bjorklund C (2015). Cereblon isoforms and their use as biomarkers for therapeutic treatment. US patent publication: US2015152511

Inventors: Trotter BWM , Hagner P , Havens GC , Chopra R, Gandhi A, Klippel A, Wang YM, Breider M, Couto SS , Ren Y, Hollenbach P, Macbeth K (2015). Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers. PCT publication no WO2015085172

Inventors: Chopra R , Hege MK (2014). Methods for treating cancer using combination therapy. PCT Publication no WO2014179661

Inventors: Thakurta A, Gandhi A, Waldman M, Chopra R (2014). Cereblon isoforms and their use as biomarkers for therapeutic treatment. PCT Publication no WO2014028445

Inventors: Schafer PH, Chopra R, Corral L, Wang MY, Jackson P, Lopez-Girona A (2014). Methods for determining drug efficacy using cereblon-associated proteins. PCT Publication no. WO2014004990

Inventors Antonia Lopez-Girona, Kristen Mae Hege, Rajesh Chopra (2014). Combination therapy comprising a TOR kinase inhibitor and an IMID compound for treating cancer. 14725324.9 - 1460. PCT publication no WO2014172429

Inventors: Schafer PH, Chopra R, Gandhi A (2014,2015). Treatment of immune-related and inflammatory diseases. PCT Publication nos WO2014025958 WO2015179279

Inventors: Treatment of cancer with tor kinase inhibitors. Shuichan X , Hege MK, Lopez-Girona A, Raymon H, Narla R, Chopra R (2013). PCT Publication no. WO2013059396

Inventors George Muller, Peter Schafer, Hon-Wah Man, Ling-Hua Zhang, Anita Gandhi, Rajesh Chopra (2012). Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione. PCT publication no WO2012125459

Inventors: Muller G, Schafer P, Man HW, Zhang LH, Gandhi, A, Chopra R (2012) Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases. PCT Publication no. WO2012125459

Professor Rajesh Chopra BSc, MBBS, FRCP, FRCPath, PhD

Inventors Sabita Sankar, Rajesh Chopra, Weiming Xu, Yuhong Ning, Shuichan Xu (2011). Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors. PCT publication no WO2011097333